Financial Performance

Vendors hold the cards in IT renewals. A new platform aims to change that by arming enterprises with pre-quote intelligence to secure better deals.

New data reveals elevated cortisol in over 75% of hard-to-treat diabetes patients, paving the way for a novel drug to tackle treatment resistance.

A single AML patient's journey to a stem cell transplant after treatment with CER-1236 offers a glimmer of hope, but is it a breakthrough or a mirage?

While CEO Craig Chambliss's EY award makes headlines, the real story is Neurelis's disruption of epilepsy care and its ambitious pipeline for brain disorders.

In an era of AI defense, Bank of America is betting on 2,500 in-person 'Scaminars.' A strategic look at why the future of fraud fighting is surprisingly human.

Legend Biotech's stunning trial results for an 'in vivo' CAR-T therapy could make advanced cancer treatment faster, safer, and accessible to all.

Kaltura’s latest awards reveal a major shift as giants like IBM and McDonald's ditch one-way messages for AI-driven conversations that anticipate user needs.

Phase 1 data for Marea Therapeutics’ MAR002 suggests a potential new era for acromegaly treatment, promising better control with far fewer injections.

Clip Money extends its debt runway, but a split among investors reveals a deeper story. Is this a savvy move to fuel expansion or a necessary patch on a leaky hull?

Iowa State University honors a key partner for securing its finances, revealing the critical, often invisible, tech that builds trust in public institutions.

Harvest's new SPXE ETF offers retail access to SpaceX's growth, but its leveraged, options-based strategy demands careful investor scrutiny.

Alexandria Real Estate's top WSJ ranking for talent readiness reveals a new playbook where human capital is the most valuable asset, even in real estate.

Flagstar Bank is ditching the 'buy' model, building its own platform and a patent-pending AI. Is this the future of banking or a costly, high-stakes gamble?

With its Calcatreu mine now in production, Patagonia Gold hires a 40-year veteran to systematically unlock the value of its 375 Argentine properties.

New drill results, including 100 metres of 1.00 g/t gold, and a fully funded feasibility study are repositioning the Spanish Mountain project's economics.

A world-first treatment in Canada saved a young burn victim's face, bypassing devastating grafts. But can this 'miracle' therapy move from one-off to standard care?

A merger of equals creates D.C.'s 7th largest bank. ODNB and NACB unite, promising big returns for investors and a new era for community banking.

Everforth ECS's third USPS supplier award isn't just a trophy; it's a signpost for how deep tech partnerships are modernizing critical public services.

As 250 million people await a drug for lymphatic diseases, Celltaxis appoints a new CEO to drive its promising inflammation-targeting therapy toward the finish line.

Tiziana Life Sciences’ chairman just increased his massive stake. We analyze if this is a vote of confidence in its novel MS drug or a risky bet on a fragile biotech.